Lundbeck Australia has announced the launch of a new antidepressant, for the treatment of major depressive disorder in adults including the prevention of relapse. This is the first new antidepressant to be introduced in Australia for almost five years. Brintellix (vortioxetine) has a novel mechanism of action and is known as mult-modal as it is
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.